NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
aripiprazole. Following intramuscular injection, aripiprazole lauroxil is likely converted by enzyme-mediated hydrolysis to N -hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in schizophrenia is unclear. However, efficacy could be…
Indications (1)
Clinical Trials (5)
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Started Dec 2019
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Started Nov 2017
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Started Dec 2015
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Started Dec 2015
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Started Dec 2014
Loss of Exclusivity
LOE Date
Apr 6, 2039
159 months away
Patent Expiry
Apr 6, 2039
Company
Alkermes
DUBLIN 4, Ireland